University of Kansas Alzheimer's Disease Research Center (KU ADRC)

堪萨斯大学阿尔茨海默病研究中心 (KU ADRC)

• 批准号: 10264622
• 负责人: RUSSELL H. SWERDLOW
• 金额: $ 303.84万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10264622
• 关键词: Address; Affect; Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer' s disease brain; Alzheimer' s disease care; Alzheimer' s disease pathology; Alzheimer' s disease patient; Alzheimer' s disease risk; Area; Automobile Driving; Back; Bioenergetics; Biological Markers; Brain; Caring; Cells; Center Core Grants; Clinic; Clinical; Clinical Trials; Collaborations; Development; Disease; Education; Energy Metabolism; Functional disorder; Funding; Gap Junctions; Genes; Genetic; Goals; Grant; Infrastructure; International; Intervention; Intervention Studies; Kansas; Knowledge; Life Style; Life Style Modification; Link; Metabolism; Mitochondria; Mitochondrial Diseases; Persons; Pharmacology; Play; Prevention; Prevention Research; Process; Proteins; Publications; Research; Research Personnel; Research Project Grants; Resources; Role; Science; Symptoms; Testing; Therapeutic; Therapeutic Intervention; Universities; Work; aging brain; bench to bedside; clinical care; clinical implementation; clinical practice; health care delivery; implementation science; innovation; lifestyle intervention; metabolic abnormality assessment; novel; programs; protein aggregation; proteostasis; ranpirnase; success; targeted treatment

ABSTRACT: OVERALL The University of Kansas Alzheimer's Disease Research Center (KU ADRC) promotes Alzheimer's Disease and Related Disorders (ADRD) research at local, national, and international levels. Our strengths in basic and translational mitochondria, lifestyle modification, and prevention research define a metabolism theme we pursued and refined over the past decade. We boast a sophisticated and mature infrastructure that advances a better understanding of AD, better care of affected persons, and new treatment interventions. The KU ADRC will use its intellectual and infrastructure assets this next cycle to drive AD research at a university vested and investing in our success, and in doing so move the field closer to a cure. Our Center moves seamlessly between bench and bedside, both in terms of the research projects we support, and in the infrastructure required to back investigator projects. Lifestyle intervention research generates fundamental mechanistic questions we call on wet lab investigators to address, and questions of clinical implementation and practice are now the focus of dry lab, clinical, and health care delivery investigators. Research addressing AD's mitochondrial component demonstrate a role for mitochondrial genes in AD risk, that mitochondria play a critical role in cell proteostasis and protein aggregation, specific links between mitochondria and AD hallmark proteins, and how to manipulate brain energy metabolism through lifestyle and pharmacologic approaches. To date these efforts led us to create novel compounds that constitute a unique therapeutic pipeline, and clinical trial infrastructure that supports actual studies of metabolism interventions in actual AD patients. For the 2021-26 cycle we will use our intellectual and infrastructure assets to address critical gaps in the AD field, including gaps in fundamental knowledge and care implementation. During this cycle the KU ADRC will work to (1) Empower innovative AD and brain aging research, education, and clinical programs; (2) Drive field-defining metabolism research, and (3) Bring practical and novel metabolism-directed therapies to the bedside and clinic.

摘要：总体 堪萨斯大学阿尔茨海默氏病研究中心（KU ADRC）促进了阿尔茨海默氏症 疾病及相关疾病（ADRD）在地方，国家和国际级别的研究。我们的优势 基本和翻译线粒体，生活方式修改和预防研究定义了新陈代谢主题 在过去的十年中，我们追求和精致。我们拥有一个复杂而成熟的基础设施 可以更好地了解AD，更好地照顾受影响的人以及新的治疗干预措施。这 KU ADRC将在下一个周期使用其智力和基础设施资产来推动大学的广告研究 归属和投资我们的成功，并这样做使该领域更接近治疗方法。 在我们的研究项目方面，我们的中心在板凳和床边之间无缝移动 支持，以及支持调查员项目所需的基础设施。生活方式干预研究 生成基本的机械问题，我们呼吁湿实验室调查人员解决，以及 临床实施和实践现在是干燥实验室，临床和医疗保健提供的重点 调查人员。针对AD的线粒体成分的研究表明了线粒体基因的作用 在AD风险中，线粒体在细胞蛋白质和蛋白质聚集中起着至关重要的作用 线粒体和AD标志性蛋白质之间，以及如何通过 生活方式和药理方法。迄今为止，这些努力使我们创造了构成的新颖化合物 独特的治疗管道和临床试验基础设施，支持代谢的实际研究 实际AD患者的干预措施。 对于2021-26周期，我们将使用我们的智力和基础设施资产来解决关键差距 广告领域，包括基本知识和护理实施方面的差距。在此周期中 将对（1）授权创新的广告和大脑老化研究，教育和临床计划； （2）开车 定义现场的新陈代谢研究，（3）将实用和新陈代谢指导的疗法带到 床边和诊所。